Manufacturer
PFIZER MANUFACTURING BELGIUM NV,
Contents
Methylprednisolone acetate
Indication
Adjuvant of a maintenance therapy & short-term administration in psoriatic arthritis, ankylosing spondylitis. Post-traumatic OA, synovitis of OA, RA eg, juvenile RA, acute & subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute gouty arthritis. Maintenance therapy in SLE, systemic dermatomyositis, acute rheumatic carditis. Pemphigus, severe erythema multiforme, exfoliative dermatitis, mycosis fungoides, bullous dermatitis herpetiformis. Chronic asthmatic resp disorders, contact & atopic dermatitis, serum sickness, seasonal or perennial allergic rhinitis, drug hypersensitivity & urticarial transfusion reactions, acute noninfectious laryngeal edema. Severe acute & chronic allergic & inflammatory eye processes. GI diseases, edematous states, resp diseases, hematologic & endocrine disorders. Palliative management of oncological diseases. Keloids, lichen planus, psoriatic plaques, granuloma annulare & lichen simplex chronicus, alopecia areata; cystic tumors or ganglia; ulcerative colitis.
Instruction
Shake thoroughly to obtain a uniform suspension.
Remove tip cap.
In a sterile way position needle.
Remove needle shield. The syringe is now ready for use.
After administration, discard the syringe. Do not reuse again.
Drug interaction
Increased renal clearance of salicylates. Inhibited metabolism by troleandomycin & ketoconazole. Enhanced metabolism & reduced effect w/ barbiturates, phenylbutazone, phenytoin or rifampicin. Reduced & increased response to anticoagulants. Increased risk of glucose intolerance w/ thiazide diuretics. Increased risk of GI ulceration w/ NSAIDs. Convulsions w/ cyclosporin.
Malaysia
